All Stories

  1. Increased plasma FGF21 level as an early biomarker for insulin resistance and metabolic disturbance in obese insulin-resistant rats

    Article • Diabetes and Vascular Disease Research, February 2018, SAGE Publications

    Dr. Pongpan Tanajak

  2. Dipeptidyl Peptidase 4 Inhibitor Vildagliptin Improves Trabecular Bone Mineral Density and Microstructure in Obese-Insulin-Resistant Rats

    Article • Canadian Journal of Diabetes, February 2018, Elsevier

    Dr. Pongpan Tanajak

  3. Dipeptidyl peptidase-4 inhibitor enhances restoration of salivary glands impaired by obese-insulin resistance

    Article • Archives of Oral Biology, January 2018, Elsevier

    Dr. Pongpan Tanajak

  4. FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats

    Article • Biomedicine & Pharmacotherapy, January 2018, Elsevier

    Dr. Pongpan Tanajak

  5. Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury

    Article • Journal of Endocrinology, November 2017, Bioscientifica

    Dr. Pongpan Tanajak

  6. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats

    Article • Toxicology and Applied Pharmacology, October 2017, Elsevier

    Dr. Pongpan Tanajak

  7. 5920Dipeptidyl peptidase-4 inhibitor markedly enhances the cardioprotective efficacy of Sodium-glucose cotransporter-2 inhibitor in pre-diabetic rats with cardiac ischemia-reperfusion injury

    Article • European Heart Journal, August 2017, Oxford University Press (OUP)

    Dr. Pongpan Tanajak

  8. Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase-4 inhibitor in prediabetic rats

    Article • Cardiovascular Therapeutics, July 2017, Wiley

    Dr. Pongpan Tanajak

  9. COMPARATIVE EFFECTS OF DDP4 INHIBITOR AND SGLT2 INHIBITOR ON BRAIN FUNCTION UNDER OBESE-INSULIN RESISTANT CONDITION

    Article • Alzheimer s & Dementia, July 2017, Elsevier

    Dr. Pongpan Tanajak

  10. Chronic treatment with prebiotics, probiotics and synbiotics attenuated cardiac dysfunction by improving cardiac mitochondrial dysfunction in male obese insulin-resistant rats

    Article • Zeitschrift für Ernährungswissenschaft, June 2017, Springer Science + Business Media

    Dr. Pongpan Tanajak

  11. FGF21 Resistance

    Article • Endocrinology, April 2017, Endocrine Society

    Dr. Pongpan Tanajak

  12. Impaired mitochondria and intracellular calcium transients in the salivary glands of obese rats

    Article • Applied Physiology Nutrition and Metabolism, April 2017, Canadian Science Publishing

    Dr. Pongpan Tanajak

  13. DPP-4 Inhibitor and Estrogen Share Similar Efficacy Against Cardiac Ischemic-Reperfusion Injury in Obese-Insulin Resistant and Estrogen-Deprived Female Rats

    Article • Scientific Reports, March 2017, Nature

    Dr. Pongpan Tanajak

  14. VAGUS NERVE STIMULATION REQUIRES BOTH IPSILATERAL AND CONTRALATERAL EFFERENT VAGAL ACTIVITY TO FULLY EXERT ITS CARDIOPROTECTION AGAINST CARDIAC ISCHEMIA/REPERFUSION INJURY

    Article • Journal of the American College of Cardiology, March 2017, Elsevier

    Dr. Pongpan Tanajak

  15. COMBINED PREBIOTICS AND PROBIOTICS TREATMENT IS NOT SUPERIOR TO SINGLE REGIMEN FOR CARDIOPROTECTION IN OBESE-INSULIN RESISTANT RATS

    Article • Journal of the American College of Cardiology, March 2017, Elsevier

    Dr. Pongpan Tanajak

  16. Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats

    Article • Journal of Endocrinology, November 2016, Bioscientifica

    Dr. Pongpan Tanajak

  17. Energy restriction combined with dipeptidyl peptidase-4 inhibitor exerts neuroprotection in obese male rats

    Article • British Journal Of Nutrition, November 2016, Cambridge University Press

    Dr. Pongpan Tanajak

  18. FGF21 improves cognition by restored synaptic plasticity, dendritic spine density, brain mitochondrial function and cell apoptosis in obese-insulin resistant male rats

    Article • Hormones and Behavior, September 2016, Elsevier

    Dr. Pongpan Tanajak

  19. Fibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homoeostasis and structural changes in pre-diabetic rats

    Article • Acta Physiologica, May 2016, Wiley

    Dr. Pongpan Tanajak

  20. Effects of fibroblast growth factor 21 on the heart

    Article • Journal of Endocrinology, September 2015, Bioscientifica

    Dr. Pongpan Tanajak